Nine multiplaintiff lawsuits accusing major pharmaceutical companies of manufacturing and selling Zantac with high levels of a cancer-causing compound will be heading back to a Connecticut state court after a federal judge concluded that the defendants failed to show there was a "mass action" to trigger federal jurisdiction.